These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34281834)

  • 21. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
    Paller CJ; Antonarakis ES
    Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
    Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
    Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.
    Mang J; Merkle K; Heller M; Schüler J; Tolstov Y; Li J; Hohenfellner M; Duensing S
    Urol Oncol; 2017 Jan; 35(1):32.e9-32.e16. PubMed ID: 27692847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.
    Kosaka T; Miyajima A; Shirotake S; Suzuki E; Kikuchi E; Oya M
    J Urol; 2011 Jun; 185(6):2376-81. PubMed ID: 21511293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
    Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
    Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide.
    Küster JHS; Erb HHH; Ahrend H; Abazid A; Stope MB
    Anticancer Res; 2024 Jul; 44(7):2815-2821. PubMed ID: 38925843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
    PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies.
    Xie B; Wan J; Chen X; Han W; Wang H
    Mol Cancer Ther; 2020 Mar; 19(3):822-834. PubMed ID: 31848296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
    Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY
    Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
    Naito R; Kano H; Shimada T; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Goto M; Nakagawa-Goto K; Mizokami A
    Prostate; 2021 Apr; 81(5):295-306. PubMed ID: 33493355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
    de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
    Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
    Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.